RxDoctor Payments Data

Anna Snow

Nurse Practitioner · Orange, MANPI 1881322626

Payments from drug & device makers

$1,054in general payments, 2019–2025

Across 43 payments — averaging $24.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$210
  • Johnson & Johnson$176
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$145
  • E.r. Squibb & Sons, L.L.C.$112
  • Indivior Inc.$94
  • AbbVie$82
  • plus $236 from 5 others

What the payments were for

  • Food & beverage$1,00595%
  • Education$495%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,054 in reported general payments places this provider in the 90th percentile of 3,855 nurse practitioner providers in Massachusetts.

See all nurse practitioner providers in Massachusetts

Medicare billing

Part B allowed, 2024
$36,023
Medicare patients
77
Services billed
328

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lurasidone Hcl67$45,462
VraylarCariprazine Hcl15$36,408
Aripiprazole107$14,414
VyvanseLisdexamfetamine Dimesylate21$7,389
Quetiapine Fumarate168$6,490
Duloxetine Hcl94$5,645
CelexaCitalopram Hydrobromide22$4,943
Buspirone Hcl149$4,868
Prazosin Hcl112$4,232
Bupropion XlBupropion Hcl86$3,351
Trazodone Hcl124$3,142
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine84$2,489
Hydroxyzine Hcl87$2,416
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine67$2,409
Topiramate53$2,180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$82$36,40815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,855 nurse practitioner providers in Massachusetts.

Other nurse practitioner in Orange

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →